Copyright
©The Author(s) 2022.
World J Clin Cases. Jul 16, 2022; 10(20): 6825-6844
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6825
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6825
Parameter | mean ± SD | Number of missing | Available % |
Time since tumor removal surgery (mo) | 2.21 ± 1.88 | – | – |
Lymphocyte-to-monocyte ratio | 4.01 ± 1.95 | 107 | 82.49% |
Neutrophil-to-lymphocyte ratio | 3.59 ± 2.82 | 273 | 55.32% |
Hemoglobin-to-platelet ratio | 0.48 ± 0.19 | 0 | 100% |
Red blood cell distribution width-to-platelet ratio | 0.058 ± 0.023 | 212 | 65.30% |
Platelet-to-lymphocyte ratio | 67.60 ± 28.82 | 266 | 56.46% |
Personalized platelet count, relative to “at-diagnosis” | 0.91 ± 0.27 | 0 | 100% |
- Citation: Herold Z, Herold M, Lohinszky J, Szasz AM, Dank M, Somogyi A. Longitudinal changes in personalized platelet count metrics are good indicators of initial 3-year outcome in colorectal cancer. World J Clin Cases 2022; 10(20): 6825-6844
- URL: https://www.wjgnet.com/2307-8960/full/v10/i20/6825.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i20.6825